BCL2-Associated Athanogene (BAG1) (N-Term) Peptide
Quick Overview for BCL2-Associated Athanogene (BAG1) (N-Term) Peptide (ABIN8095458)
Target
Origin
Source
Application
-
-
Protein Region
- N-Term
-
Purpose
- BAG1 Peptide - N-terminal region
-
Sequence
- LIFKGKSLKE METPLSALGI QDGCRVMLIG KKNSPQEEVE LKKLKHLEKS
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
This is a synthetic peptide designed for use in combination with anti-BAG1 Antibody (ARP63477_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Buffer
- Lyophilized powder
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- BAG1 (BCL2-Associated Athanogene (BAG1))
-
Background
-
Background Information: The oncogene BCL2 is a membrane protein that blocks a step in a pathway leading to apoptosis or programmed cell death. The protein encoded by this gene binds to BCL2 and is referred to as BCL2-associated athanogene. It enhances the anti-apoptotic effects of BCL2 and represents a link between growth factor receptors and anti-apoptotic mechanisms. Multiple protein isoforms are encoded by this mRNA through the use of a non-AUG (CUG) initiation codon, and three alternative downstream AUG initiation codons. A related pseudogene has been defined on chromosome X.
Alternative Symbols: HAP, RAP46
-
Molecular Weight
- 25kDa
-
Gene ID
- 573
-
NCBI Accession
- NP_001165886
-
UniProt
- Q99933
Target
-
